PD 169316, >=98% (HPLC), solid

Not available outside of the UK & Ireland.

Application

PD 169316 has been used for the inhibition of p38 enzyme in human hepatocytes. It has been used in culture media to promote embryoid bodies differentiation.

Biochem/physiol Actions

Potent, cell-permeable and selective p38 MAP kinase inhibitor (IC₅₀ = 89 nM).

Features and Benefits

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

General description

PD 169316 is a pyridinyl imidazole compound. It is a potential inhibitor of p38 mitogen-activated protein kinases. It also inhibits signalling transforming growth factor β (TGFβ), particularly in human ovarian cancer cells.

Packaging

5, 25 mg in glass bottle